Fluticasone is a synthetic corticosteroid developed in the late 20th century and widely introduced into medical use during the 1990s. It is used primarily for its potent anti-inflammatory and immunosuppressive effects in conditions such as asthma, allergic rhinitis, and various inflammatory skin disorders. Fluticasone works by binding to glucocorticoid receptors and regulating gene expression to reduce the production of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It is available in multiple formulations, including inhaled, intranasal, and topical preparations, allowing targeted delivery to the lungs, nasal passages, or skin with minimal systemic absorption. Over time, fluticasone became a key component in combination therapies, particularly in asthma management when paired with long-acting bronchodilators. Its development significantly improved long-term control of chronic inflammatory airway diseases while minimizing systemic corticosteroid side effects.
BRAND NAMES
Flixotide (inhaled fluticasone for asthma/COPD)
Flonase (fluticasone nasal spray for allergic rhinitis; widely used in the US and other countries)
Cutivate (topical fluticasone for skin conditions like eczema and dermatitis)
Seretide / Advair (combination products containing fluticasone + a long-acting bronchodilator such as salmeterol)
MECHANISM OF ACTION
Fluticasone is a synthetic glucocorticoid that exerts its effects by binding to intracellular glucocorticoid receptors in target cells. Once the fluticasone–receptor complex is formed, it translocates to the nucleus, where it modulates gene transcription by increasing the expression of anti-inflammatory proteins and suppressing pro-inflammatory genes. This leads to reduced production of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes.
PHARMACOKINETICS:
Absorption:
Absorption:
Fluticasone has very low systemic absorption due to its high lipophilicity and extensive first-pass metabolism. When administered via inhalation, only a small fraction reaches systemic circulation, with most of the dose deposited in the lungs and swallowed portion undergoing rapid hepatic metabolism.
Distribution:
Any absorbed fluticasone is highly protein-bound in plasma and is widely distributed in tissues. However, systemic exposure remains very low due to rapid clearance and strong receptor affinity at local sites of action.
Metabolism:
Fluticasone is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4, into inactive metabolites. This high first-pass metabolism significantly reduces systemic availability.
Elimination:
Metabolites of fluticasone are excreted mainly in the feces via biliary elimination, with a minor portion eliminated in urine. The terminal half-life is relatively long, but systemic concentrations remain low due to minimal absorption.
PHARMACODYNAMICS
Fluticasone is a synthetic corticosteroid with potent anti-inflammatory activity that acts by binding to intracellular glucocorticoid receptors. After receptor activation, the fluticasone–receptor complex translocates to the nucleus where it regulates gene transcription, upregulating anti-inflammatory proteins and downregulating pro-inflammatory mediators such as cytokines, prostaglandins, and leukotrienes.
ADMINISTRATION
Fluticasone is administered via inhalation, intranasal spray, or topical application depending on the condition being treated. Inhaled formulations are used for asthma and chronic obstructive pulmonary disease (COPD), intranasal sprays are used for allergic rhinitis, and topical preparations are used for inflammatory skin conditions such as eczema and dermatitis.
DOSAGE AND STRENGTH
Fluticasone dosage varies depending on the route of administration and severity of disease. Inhaled doses for asthma are usually expressed in micrograms per day and adjusted based on disease control, while intranasal sprays are commonly used once or twice daily depending on formulation strength. Topical preparations are applied in thin layers once or twice daily to affected skin areas.
DRUG INTERACTIONS
Fluticasone is metabolized primarily by the CYP3A4 enzyme system, so drugs that strongly inhibit CYP3A4 (such as certain antifungals and antivirals) may increase systemic exposure and the risk of corticosteroid-related side effects. Concomitant use with other corticosteroids may increase the risk of cumulative steroid effects.
FOOD INTERACTIONS
Fluticasone does not have significant clinically relevant food interactions. Its activity is primarily local (inhaled, nasal, or topical), and food does not affect its efficacy or absorption in a meaningful way.
CONTRAINDICATIONS
Fluticasone is contraindicated in patients with known hypersensitivity to fluticasone or any component of the formulation. It should be used cautiously in patients with untreated localized infections (bacterial, fungal, or viral) unless appropriate antimicrobial therapy is also provided. Long-term or high-dose use should be avoided without medical supervision due to risk of systemic corticosteroid effects.
SIDE EFFECTS
Local irritation (nasal, throat, or skin)
Dryness of nasal passages or skin
Hoarseness or sore throat (inhaled form)
Cough (inhaled form)
Nosebleeds (intranasal form)
Headache
Oral candidiasis (thrush, with inhaled use if mouth not rinsed)
Skin thinning (with prolonged topical use)
Rare: mild systemic corticosteroid effects at high doses
OVER DOSAGE
Fluticasone overdose is uncommon because the drug is designed for local action with minimal systemic absorption when used at recommended doses. However, excessive or prolonged use, particularly at high doses or in combination with strong CYP3A4 inhibitors, can increase systemic exposure and lead to corticosteroid-related effects.
TOXICITY
Fluticasone toxicity is uncommon due to low systemic absorption at recommended doses. However, prolonged high-dose use or strong CYP3A4 inhibition can increase systemic exposure, potentially leading to hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushingoid features, adrenal suppression, and growth suppression in children.
